Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

A former AstraZeneca employee allegedly engaged in insider trading while at the Big Pharma, according to an SEC complaint submitted last week.

In March 2019, Hugues Pierre Joublin learned the company was in confidential negotiations with Daiichi Sankyo for a global development and commercialization pact for Daiichi’s antibody that would come to be known as Enhertu. He was global head of corporate affairs for AZN’s oncology division at the time, when he learned of the deal negotiations on March 6.